EMA Authorised: Bortezomib Fresenius Kabi (bortezomib) — Fresenius Kabi Deutschland GmbH

View source ↗

Summary

The European Medicines Agency authorised Bortezomib Fresenius Kabi for the treatment of multiple myeloma, with the active substance bortezomib, under the market…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib Fresenius Kabi (bortezomib)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Fresenius Kabi Deutschland GmbH. Decision date: 13/02/2025